RGLS : Summary for Regulus Therapeutics Inc. - Yahoo Finance

U.S. Markets open in 5 hrs 12 mins

Regulus Therapeutics Inc. (RGLS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.50-0.20 (-11.76%)
At close: 4:00PM EDT
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close1.70
Bid1.00 x 3000
Ask1.70 x 600
Day's Range1.35 - 1.80
52 Week Range0.94 - 8.90
Avg. Volume1,131,727
Market Cap79.4M
PE Ratio (TTM)-0.97
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Business Wire13 hours ago

    IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Regulus Therapeutics Inc. and Encourages Investors With Losses to Contact the Firm

    Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Regulus Therapeutics Inc. concerning possible violations of federal securities laws between January 21, 2016 and June 27, 2016 inclusive .

  • GlobeNewswire16 hours ago

    INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Commenced a Class Action on Behalf of Shareholders of Regulus Therapeutics Inc. -- Lead Plaintiff Deadline of April 3, 2017

    NEW YORK, March 28, 2017-- The following statement is being issued by Levi & Korsinsky, LLP:. To: All persons or entities who purchased or otherwise acquired shares of Regulus Therapeutics Inc. between ...

  • Regulus to Present at the 16th Annual Needham Healthcare Conference
    PR Newswire20 hours ago

    Regulus to Present at the 16th Annual Needham Healthcare Conference

    Regulus Therapeutics Inc. (RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs.  Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate to retain its leadership in the microRNA field.  Regulus is advancing several programs in renal, hepatic and central nervous systems diseases, both independently and with our strategic alliance partners, Sanofi and AstraZeneca. Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Regulus to undertake certain activities and accomplish certain, the projected timeline of clinical development activities, and expectations regarding future therapeutic and commercial potential of Regulus' business plans, technologies and intellectual property related to microRNA therapeutics and biomarkers being discovered and developed by Regulus.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.